Showing results (971-980 of 1,007) with videos related to

Sort By:
Pageof 101
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Medrxiv : the Preprint Server for Health Sciences|August 6, 2025
Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humansHenning Tim Langer, Natalie K Gilmore, Chris M T Hayden, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Leukemia|May 26, 2018
Consequences of mutant TET2 on clonality and subclonal hierarchyCassandra M Hirsch, Aziz Nazha, Kassy Kneen, et al.
Blood|November 8, 2021
The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disordersSimona Pagliuca, Carmelo Gurnari, Hassan Awada, et al.
Gynecologic Oncology|September 12, 2024
Cervical squamous cell carcinoma outcomes across continents: A retrospective studyDeepti Jain, Fadi Zaeim, Marya Wahidi, et al.
Cancer Medicine|May 31, 2021
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE studyAmélie Deleporte, Marc Van den Eynde, Frédéric Forget, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Pageof 101